In the IMpassion130 randomized clinical trial, which randomized patients to first-line atezolizumab or placebo plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer, the improvement OS in the intent-to-treat population was not statistically significant, but the 3-year OS rates in the PD-L1 IC-positive population were 35.8% with atezolizumab plus nab-paclitaxel versus 22.2% with placebo plus nab-paclitaxel (17). This evidence concerns the gene CD274 and triple-negative breast carcinoma.